Form 4: MediWound Director Acquires Shares, Options

MediWound Ltd. director David Morton Fox reported the acquisition of ordinary shares and the grant of stock options on June 1, 2026.

Summary

• David Morton Fox, a Director at MediWound Ltd., reported transactions on June 1, 2026.
• He acquired 1,730 ordinary shares at $14.225 per share.
• He also acquired 10 ordinary shares at $14.23 per share.
• Additionally, he acquired 1,797 ordinary shares at $13.995 per share.
• The filing also notes the grant of stock options and underlying shares for informational purposes, with some granted on March 4, 2026, vesting one year after the grant date.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as director share purchases can indicate confidence, but the filing itself is purely transactional and lacks broader strategic or financial updates.

Positives

• Director acquisition of shares can signal confidence in the company's future prospects.
• The acquisition of a significant number of shares (over 3,500 in total from the reported transactions) by a director is generally viewed positively by the market.

Future Outlook

The filing does not contain forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that insider transactions, such as director share purchases, are closely watched by investors as they can provide insights into management's perception of the company's value and future performance within the biotechnology sector.

Stakeholder Impact

• Shareholders may view the director's share purchases as a positive signal of confidence in the company's future.
• Employees may interpret these transactions as a sign of management's commitment to the company's success.

Key Dates

Keywords

MediWound Ltd., MDWD, Form 4, Insider Trading, Director Transactions, Stock Options, Share Acquisition